The Future of COVID Testing

4 min read

Pitfalls and opportunities We are all appalled by the feeble US response to the need for COVID testing. This failure was due to misaligned incentives. With no path to monetize infectious disease testing, we did not innovate and could not execute. That’s the past. What about the future? If you have been paying attention to the testing story, you know at least two things: RT-PCR (and also a variant called ITA) testing can diagnose new infections and thus determine who needs medical attention Antibody testing (serology) identifies people who are immune, and thus are key to reopening the economy The…...

This content is for DDI Basic Membership only.
Join Now
Already a member? Log in here
Drew Smith Drew Smith holds a PhD in molecular biology and has worked as a bench scientist, R&D Director, CSO, CEO and founder at several biotech and medtech startups.